Viking expects to report data from the study in the second half of 2025. The Phase 2 VENTURE-Oral Dosing Trial is a randomized, double-blind, placebo-controlled multicenter study designed to ...

The Minnesota Vikings find themselves in an interesting spot. After a stellar free agency period during which they got stronger at almost every position, ...

interest in participating in the Phase 2 VENTURE-Oral study was high and drove an efficient rate of enrollment," said Brian Lian, Ph.D., chief executive officer of Viking Therapeutics.